Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic, reversible grade ...
Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have ...
ORLANDO -- Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective ...
Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...
The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research ...
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...
A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.
GLP-1 receptor agonist therapy reduced surgical abscess repairs and hospitalizations among people with hidradenitis ...
USA: A retrospective comparative effectiveness study among veterans with type 2 diabetes found that three GLP-1 receptor ...
GLP-1 receptor agonists lead a new wave of therapeutic options that may benefit patients with osteoarthritis, according to data presented at the 2025 Congress of Clinical Rheumatology West.“This field ...
HealthDay on MSN
CHEST: Mortality Down With GLP-1 Receptor Agonist Use in T2D, Especially in Those With OSA
Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network to examine whether OSA modifies outcomes in patients with T2DM receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback